Result of Shareholder Analysis

Summary by AI BETAClose X

CRISM Therapeutics Corporation has announced the results of an independent shareholder register analysis as of June 30, 2026, identifying significant shareholders with interests of 3% or more in the company's ordinary share capital. The Miton UK Smaller Companies Fund holds the largest stake at 9.47%, followed by Mr. Andrew Webb with 9.22%, and Dr. Christopher McConville with 6.30%. Other substantial shareholders include Mr. Brian Murray (6.20%), Mr. David Lawton (5.07%), Zeus Dynamic Opportunities Fund (3.98%), Hobart Capital Markets LLP (3.57%), and Mr. John Rylands (3.02%).

Disclaimer*

UK 100

Latest directors dealings